MX2023010840A - Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. - Google Patents

Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.

Info

Publication number
MX2023010840A
MX2023010840A MX2023010840A MX2023010840A MX2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A MX 2023010840 A MX2023010840 A MX 2023010840A
Authority
MX
Mexico
Prior art keywords
methods
related compositions
activatable
cytokine
constructs
Prior art date
Application number
MX2023010840A
Other languages
English (en)
Spanish (es)
Inventor
Alexey Yevgenyevich Berezhnoy
Sayantan Mitra
Nicole G Lapuyade
Hikmat Haizar Assi
Madan M Paidhungat
Dylan L Daniel
Walter A Bogdanoff
Na Cai
Scolan Erwan Le
Hsin Wang
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of MX2023010840A publication Critical patent/MX2023010840A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023010840A 2021-03-16 2022-03-16 Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados. MX2023010840A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163161913P 2021-03-16 2021-03-16
US202163164827P 2021-03-23 2021-03-23
US202163254748P 2021-10-12 2021-10-12
US202163276893P 2021-11-08 2021-11-08
PCT/US2022/020492 WO2022197764A2 (en) 2021-03-16 2022-03-16 Masked activatable cytokine constructs and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2023010840A true MX2023010840A (es) 2023-10-26

Family

ID=81389111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010840A MX2023010840A (es) 2021-03-16 2022-03-16 Construcciones de citocinas activables enmascaradas y composiciones y métodos relacionados.

Country Status (11)

Country Link
US (2) US11667687B2 (cg-RX-API-DMAC7.html)
EP (1) EP4308594A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024511387A (cg-RX-API-DMAC7.html)
KR (1) KR20230157448A (cg-RX-API-DMAC7.html)
AU (1) AU2022237504B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023018735A2 (cg-RX-API-DMAC7.html)
CA (1) CA3211924A1 (cg-RX-API-DMAC7.html)
IL (1) IL305716A (cg-RX-API-DMAC7.html)
MX (1) MX2023010840A (cg-RX-API-DMAC7.html)
TW (1) TW202304958A (cg-RX-API-DMAC7.html)
WO (1) WO2022197764A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
MX2024004301A (es) * 2021-10-08 2024-04-26 Cytomx Therapeutics Inc Construcciones de citocinas activables y metodos combinados.
EP4694934A1 (en) 2023-04-12 2026-02-18 CytomX Therapeutics, Inc. Masking polypeptides, activatable cytokine constructs, and related compositions and methods
CN119234000B (zh) * 2023-09-25 2026-04-17 深圳湾实验室 可激活穿膜构建体和降解子
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1286700A2 (en) 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
JP4334866B2 (ja) 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
GB0100551D0 (en) 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
CN101184771A (zh) 2005-05-26 2008-05-21 先灵公司 干扰素-IgG融合体
EP1993608A1 (en) 2006-03-10 2008-11-26 Diatos Anticancer drugs conjugated to antibody via an enzyme cleavable linker
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
WO2009079837A1 (en) 2007-12-18 2009-07-02 Hangzhou Jiuyuan Gene Engineering Co., Ltd. A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
HRP20150664T1 (hr) 2010-12-03 2015-07-31 Adamed Sp. Z O.O. Antikancerogeni fuzijski protein
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
US20190216898A1 (en) 2016-05-06 2019-07-18 Wang Mulin Interleukin Combination and Use Thereof
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
JP2020528878A (ja) * 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US12564632B2 (en) 2017-11-08 2026-03-03 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
CN111954680B (zh) 2017-11-10 2024-03-15 新加坡科技研究局 IL2Rβ/共同γ链抗体
JP7386161B2 (ja) 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
WO2020113403A1 (en) 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
CN112351946B (zh) 2018-06-21 2022-07-08 Tgw物流集团有限公司 货仓及拣选系统和用于从悬挂袋和其他装载辅助器具中拣选订单货物的方法
MX2020014290A (es) 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
WO2020041758A1 (en) 2018-08-24 2020-02-27 City Of Hope Masked cytokine conjugates
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
CA3114179A1 (en) * 2018-09-28 2020-04-02 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
WO2020123980A1 (en) 2018-12-14 2020-06-18 Proviva Therapeutics (Hong Kong) Limited Il-15 compositions and methods of use thereof
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
AU2020285636A1 (en) 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
KR20260089650A (ko) 2019-07-12 2026-06-15 프로비바 테라퓨틱스 (홍콩) 리미티드 Il-2 조성물 및 이의 사용 방법
AU2020316002B2 (en) 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
EP4013775A1 (en) 2019-08-12 2022-06-22 Askgene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
WO2021062406A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
WO2021113577A1 (en) 2019-12-05 2021-06-10 Immune Targeting Inc. Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
AU2020403148A1 (en) 2019-12-13 2022-06-30 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
US20240043489A1 (en) 2020-01-15 2024-02-08 Trutino Biosciences Inc. Cytokine Prodrugs Comprising a Cleavable Linker
MX2022011676A (es) 2020-03-23 2023-03-08 Zymeworks Bc Inc Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
US20230226202A1 (en) 2020-03-30 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Il-2/il15 compositions and methods of use thereof
PH12022552627A1 (en) 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-2 cytokines and their cleavage products
PH12022552630A1 (en) 2020-04-01 2023-01-04 Xilio Dev Inc Masked il-15 cytokines and their cleavage products
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
CA3178657A1 (en) 2020-05-19 2021-11-25 William Winston Activatable il-12 polypeptides and methods of use thereof

Also Published As

Publication number Publication date
WO2022197764A2 (en) 2022-09-22
IL305716A (en) 2023-11-01
US20240124546A1 (en) 2024-04-18
US20220306717A1 (en) 2022-09-29
TW202304958A (zh) 2023-02-01
AU2022237504B2 (en) 2026-06-04
CA3211924A1 (en) 2022-09-22
AU2022237504A1 (en) 2023-10-05
WO2022197764A3 (en) 2022-11-03
EP4308594A2 (en) 2024-01-24
JP2024511387A (ja) 2024-03-13
US11667687B2 (en) 2023-06-06
BR112023018735A2 (pt) 2023-11-28
KR20230157448A (ko) 2023-11-16

Similar Documents

Publication Publication Date Title
MX2022012592A (es) Construcciones de citocinas activables y composiciones y metodos relacionados.
WO2022197764A3 (en) Masked activatable cytokine constructs and related compositions and methods
MX2024004301A (es) Construcciones de citocinas activables y metodos combinados.
Salamonsen et al. Regulation of matrix metalloproteinases in human endometrium
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
WO2023060156A3 (en) Activatable cytokine constructs and related compositions and methods
GB2378591A (en) RF power amplifier and methods for improving the efficiency thereof
EP4442220A3 (en) Medical device systems and computer-readable mediums for operating the same
CN104702224A (zh) Rf功率放大和分配系统、等离子点火系统及其操作方法
WO2022216386A3 (en) T-type calcium channel antagonists and uses thereof
WO2022192439A8 (en) Improving immune cell function
GB0315599D0 (en) Cartesian loop transmitter and method of adjusting an output level of such transmitter
Van de Scheur et al. Pericapillary fibrin cuffs in venous disease: a reappraisal
BR0208694A (pt) Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária
Yamabe et al. Thrombin stimulates production of transforming growth factor-beta by cultured human mesangial cells.
ZA202300222B (en) Anti-αlpha-4-βeta-7 antibodies
WO2012146015A1 (zh) 功率放大装置及功放电路
CN102891665A (zh) 全固态发射机脉冲调制波形的频谱控制方法
GB672865A (en) Improvements in and relating to radio ranging systems
AR125090A1 (es) Construcciones de citoquinas activables enmascaradas y composiciones y métodos relacionados
Shen et al. The environmental and economic effects of differentiated carbon tax across industries under the constraint of the “dual carbon” goal: A study based on a dynamic CGE model
WO2023086871A3 (en) Human tumor necrosis factor alpha antibodies
CN104836536A (zh) 一种基于负反馈的功率放大器结构
AR127274A1 (es) Construcciones de citoquinas activables, y métodos de combinación
DK0651654T3 (da) Anvendelse af lysozymdimer til fremstilling af et lægemiddel til styrkelse af de naturlige forsvarsmekanismer